Enzymatic studies of isoflavonoids as selective and potent inhibitors of human leukocyte 5-lipo-oxygenase

Chemical Biology and Drug Design

Volumn 86, Issue 1, 2015, Pages 894-901

  Mascayano, Carolina ^a   Espinosa, Victoria ^a   Sepúlveda Boza, Silvia ^a   Hoobler, Eric K ^b   Perry, Steve ^b   Diaz, Giovanni ^b   Holman, Theodore R ^b  

^a UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

human lipo oxygenase; IC50< inf> values, structure activity relationship; isoflavans derivative; steered molecular dynamics

Indexed keywords

BAICALEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ISOFLAVONOID; LIPOXYGENASE INHIBITOR; ALOX5 PROTEIN, HUMAN; ARACHIDONATE 5 LIPOXYGENASE; FLAVONOID;

ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LEUKOCYTE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; ENZYMOLOGY; METABOLISM; SHEEP; SYNTHESIS;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; FLAVONOIDS; HUMANS; LEUKOCYTES; LIPOXYGENASE INHIBITORS; MOLECULAR DYNAMICS SIMULATION; SHEEP;

EID: 84931291856     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12469     Document Type: Article

References (36)

1. Yamamoto S., (1992) Lipoxygenases: molecular structures and functions. Biochim Biophys Acta; 1128: 117-131.
2. Malhotra S., Deshmukh S.S., Dastidar S.G., (2012) COX inhibitors for airway inflammation. Expert Opin Ther Targets; 16: 195-207.
3. Pontiki E., (2008) Lipoxygenase inhibitors: a comparative QSAR study review and evaluation of new QSARs. Med Res Rev; 28: 39-117.
4. Ji R.R., Xu Z.Z., Strichartz G., Serhan C.N., (2011) Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci; 34: 599-609.
5. Kelavkar U.P., Cohen C., Kamitani H., Eling T.E., Badr K.F., (2000) Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging. Carcinogenesis; 21: 1777-1787.
6. Ding X.Z., Iversen P., Cluck M.W., Knezetic J.A., Adrian T.E., (1999) Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun; 261: 218-223.
7. Bozza P.T., Bakker-Abreu I., Navarro-Xavier R.A., Bandeira-Melo C., (2011) Lipid body function in eicosanoid synthesis: an update. PLEFA; 85: 205-213.
8. Riccioni G., Bäck M., Capra V., (2010) Leukotrienes and atherosclerosis. Curr Drug Targets; 11: 882-887.
9. Moreno J.J., (2005) Arachidonic acid cascade enzyme inhibition and cancer. Curr Enzyme Inhib; 1: 131-145.
10. Mitjavilaa M., Moreno J.J., (2012) The effects of polyphenols on oxidative stress and the arachidonic acid cascade. Implications for the prevention/treatment of high prevalence diseases. Biochem Pharmacol; 84: 1113-1122.
11. Voss C., Sepulveda-Boza S., Zilliken F.W., (1992) New isoflavonoids as inhibitors of porcine 5-lipoxygenase. Biochem Pharmacol; 44: 157-162.
12. Vasquez-Martinez Y., Ohri R.V., Kenyon V., Holman T.R., Sepúlveda-Boza S., (2007) Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2. Bioorg Med Chem; 15: 7408-7425.
13. Mascayano C., Espinosa V., Sepúlveda-Boza S., Hoobler E.K., Perry S., (2013) In vitro study of isoflavones and isoflavans as potent inhibitors of human 12- and 15-lipoxygenases. Chem Biol Drug Des; 82: 317-325.
14. Sepúlveda-Boza S., Walizei G.H., Caroli-Rezende M., Vásquez Y., Mascayano C., Mejías L., (2001) The preparation of new isoflavones. Synthetic Comm; 31: 1933-1940.
15. Albert A.I., Zilliken F.W., (1989) U.S. Patent 4 814, 346.
16. Zilliken F.W., (1984) EP0027796B1.
17. Tang L.J., Chen X., Sun Y.N., Ye J., Lu J., Han Y., Jiang X., Cheng C.C., He C.C., Qiu P.H., Li. X.K., (2011) Synthesis and biological studies of 4′, 7, 8-trihydroxy-isoflavone metal complexes. J Inorg Biochem; 105: 1623-1629.
18. Robinson S.J., Hoobler E.K., Riener M., Loveridge S.T., Tenney K., Valeriote F.A., Holman T.R., Crews P., (2009) Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod; 72: 1857-1863.
19. Ohri R.V., Radosevich A.T., Hrovat K.J., Musich C., Huang D., Holman T.R., Toste F.D., (2005) A Re(V)-catalyzed C-N bond-forming route to human lipoxygenase inhibitors. Org Lett; 9: 2501-2504.
20. Riendeau D., Falgueyret J.P., Guay J., Ueda N., Yamamoto S., (1991) Pseudoperoxidase activity of 5-lipoxygenase stimulated by potent benzofuranol and N-hydroxyurea inhibitors of the lipoxygenase reaction. Biochem J; 274: 287-292.
21. Rai G., Kenyon V., Jadhav A., Schultz L., Armstrong M., Jameson J.B., Hoobler E., Leister W., Simeono A., Holman T.R., Maloney D.J., (2010) Discovery of potent and selective inhibitors of human reticulocyte 15-lipoxygenase-1. J Med Chem; 53: 7392-7404.
22. Spaethe S.M., Snyder D.W., Pechous P.A., Clarke T., Van Alstyne E.L., (1992) Guinea pig whole blood 5-lipoxygenase assay: utility in the assessment of potential 5-lipoxygenase inhibitors. Biochem Pharmacol; 43: 377-382.
23. Frisch M.J., Trucks G.W., Schlegel H.B., Scuseria G.E., Robb M.A., Cheeseman J.R., Scalmani G., et al,. (2009) Gaussian 09, Revision A.1. Wallingford CT: Gaussian, Inc.
24. Gilbert N.C., Bartlett S.G., Waight M.T., Neau D.B., Boeglin W.E., Brash A.R., Newcomer M.E., (2011) The structure of human 5-lipoxygenase. Science; 331: 217-219.
25. Xu S., Mueser T.C., Marnett L.J., Funk M.O., (2012) Crystal structure of 12-lipoxygenase catalytic-domain-inhibitor complex identifies a substrate-binding channel for catalysis. Structure; 20: 1490-1497.
26. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J.J., (1998) Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. Comput Chem; 19: 1639-1662.
27. Kale L., Skee L.R., Bhandarkar M., Brunner R., Gursoy A., Krawetz N., Phillips J., Shinozaki A., Varadarajan K., Schulten K., (1999) NAMD2: greater scalability for parallel molecular dynamics. J Comput Phys; 151: 283-312.
28. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M., (1983) CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comp Chem; 4: 187-217.
29. Humphrey W., Dalke A., Schulten K., (1996) VMD-visual molecular dynamics. J Mol Graphics; 14: 33-38.
30. Deschamps J.D., Kenyon V.A., Holman T.R., (2006) Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases. Bioorg Med Chem; 14: 4295-4301.
31. Mascayano C., Caroli M., Rivera Y., Espinosa V., (2011) Isoflavans derivatives as inhibitors of soybean lipoxygenase: in-vitro and docking studies. J Child Chem Soc; 56: 935-937.
32. Solomon E.I., Zhou J., Neese F., Pavel E.G., (1997) New insights from spectroscopy into the structure/function relationships of lipoxygenases. Chem Biol; 4: 795-808.
33. Dunham W.R., Carroll R.T., Thompson J.F., Sands R.H., Funk M.O. Jr, (1990) The initial characterization of the iron environment in lipoxygenase by Mössbauer spectroscopy. Eur J Biochem; 190: 611-617.
34. Hoobler E.K., Holz C., Holman T.R., (2013) Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases. Bioorg Med Chem; 21: 3894-3899.
35. Baumann J., Bruchhausen F., Wurm G., (1980) Flavonoids and related compounds as inhibition of arachidonic acid peroxidation. Prostaglandins; 20: 627-639.
36. Tang S., Bhatia B., Maldonado C.J., Yang P., Newman R.A., Liu J., Chandra D., Traag J., Klein R.D., Fischer S.M., Chopra D., Shen J., Zhau H.E., Chung L.W., Tang D.G., (2002) Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem; 277: 16189-16201.